Your browser doesn't support javascript.
Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19.
Milross, Luke; Majo, Joaquim; Cooper, Nigel; Kaye, Paul M; Bayraktar, Omer; Filby, Andrew; Fisher, Andrew J.
  • Milross L; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK.
  • Majo J; Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Cooper N; Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Kaye PM; York Biomedical Research Institute, Hull York Medical School, University of York, York, UK.
  • Bayraktar O; Cellular Genetics Institute, Wellcome Sanger Institute, Cambridge, UK.
  • Filby A; Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Fisher AJ; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK; Institute of Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: a.j.fisher@newcastle.ac.uk.
Lancet Respir Med ; 10(1): 95-106, 2022 01.
Article in English | MEDLINE | ID: covidwho-1612130
ABSTRACT
The lungs are the main site that is affected in severe COVID-19, and post-mortem lung tissue provides crucial insights into the pathophysiology of severe disease. From basic histology to state-of-the-art multiparameter digital pathology technologies, post-mortem lung tissue provides snapshots of tissue architecture, and resident and inflammatory cell phenotypes and composition at the time of death. Contrary to early assumptions that COVID-19 in the lungs is a uniform disease, post-mortem findings have established a high degree of disease heterogeneity. Classic diffuse alveolar damage represents just one phenotype, with disease divisible by early and late progression as well as by pathophysiological process. A distinct lung tissue state occurs with secondary infection; extrapulmonary causes of death might also originate from a pathological process in the lungs linked to microthrombosis. This heterogeneity of COVID-19 lung disease must be recognised in the management of patients and in the development of novel treatment strategies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Type of study: Prognostic study Limits: Humans Language: English Journal: Lancet Respir Med Year: 2022 Document Type: Article Affiliation country: S2213-2600(21)00408-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Type of study: Prognostic study Limits: Humans Language: English Journal: Lancet Respir Med Year: 2022 Document Type: Article Affiliation country: S2213-2600(21)00408-2